Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

CRH Medical Corporation T.CRH

Sector: Healthcare | Sub-Sector: Medical Instruments & Supplies

CRH Medical Corp provides physicians with products for the treatment of gastrointestinal diseases. Its product is a single use, disposable, hemorrhoid technology used in treating hemorrhoid grades I - IV.
Price: $3.60 | Change: +$0.05 | %Change: +1.41%
Volume: 315,223 | Day High/Low: 3.70/3.55 | 52 Week High/Low: 4.15/0.61
View modes: 
0 stars

Acumen Capital Ups Target to $5.80

Acumen Capital raises price target of CRH Medical to $5.80 (up) from $5.50 March 27, 2015. Rated BUY.  rate and reply
5 stars

For Heath Care: Don"t go away in May this year  rate and reply
0 stars

RE:RE:RE:New Coverage

Nice new coverage.  rate and reply
0 stars

RE:RE:New Coverage

Clarus has a bit more clarity and oomph behind it. Beacon isn't all that well respected on the street and to institutions. I'm not suggest Clarus is miles ahead of them, but just slightly better.  rate and reply
5 stars

RE:New Coverage

I like Beacon's $6.00 target price more.  rate and reply
0 stars

New Coverage

CRH Medical Corp. was rated new “buy” at Clarus Securities. The 12-month target price is $5.25 (Canadian) per share  rate and reply
5 stars

Another report

Clarus initiated with a 5.25 target.  Waking Up to Ample Booty We are initiating coverage on CRH Medical Corporation with a BUY recommendation and a 12-month target price of $5.25 per more
0 stars

RE:RE:RE:RE:RE:RE:RE:Nice to have Bloom Burton advising M&A

they have two funds that are open up for investment. There's an equity fund and a debt one if i'm not mistaken. I've personally invested in both funds as i'm big a believer that they know what more
0 stars

RE:RE:RE:RE:RE:RE:Nice to have Bloom Burton advising M&A

A Bloom Burton ETF would be interesting.  rate and reply
0 stars

RE:Knight Therapeutics' Secured Lending Strategy Validated by C

Now that Knight has dumped their 3 million shares that might take some of the selling pressure out of this stock.  rate and reply
0 stars

Knight Therapeutics' Secured Lending Strategy Validated by C

Knight Therapeutics' Secured Lending Strategy Validated by CRH Medical Corporation MONTREAL, CANADA--(Marketwired - March 25, 2015) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the more
0 stars

RE:RE:RE:RE:RE:Nice to have Bloom Burton advising M&A

they are the only legit healthcare boutique firm in canada. They are truly specialists and great at what they do.  rate and reply
0 stars

RE:RE:RE:RE:Nice to have Bloom Burton advising M&A

Looks like they are all over the whole industry.  rate and reply
0 stars

RE:RE:RE:Nice to have Bloom Burton advising M&A

they also lent the company money and helped with the recent acquisition. They are all over it.  rate and reply
0 stars

RE:RE:Nice to have Bloom Burton advising M&A

  rate and reply
0 stars

RE:Nice to have Bloom Burton advising M&A

[img]http://[/img]  rate and reply
0 stars

Nice to have Bloom Burton advising M&A

Check out what they are doing in Healthcare  rate and reply
0 stars


Paid off 10 mil in debt to Knight which saves about 1 mil @ yr in interest, and leaves about 17 mil in the bank, a nice chunk of change left over for aquisitions.  rate and reply
0 stars

Fundamentally Sound!

Crh are technically sound at this point..Fundamentally , with financing done it is bound to run, in short term as the smart money shakes the weak stockholders to sell their shares we will have more
0 stars

More Technical Analysis

The Pull Back Play strategy looks for stocks in strong long term upward trends but which have pulled back in the short term. The final step is to inspect the charts of these stocks to see if they more